CD8A and B-cell chronic lymphocytic leukemia: Recent studies revealed that ibrutinib combined with rituximab enhances anti-CLL T cell cytotoxicity, shifting from CD4 + T cell immune synapse to increased CD8 + lytic synapse during therapy [39].